The total global ophthalmology market targeted by Icon Bioscience, Inc. is estimated to be in excess of $20 billion and expected to rise. In addition, the global population of diabetes is expected to increase significantly in the upcoming decades. Intraocular injections have already become state of the art for controlling and treating complications arising from diabetic retinopathy.
As the global population ages, the prevalence of more age related diseases, such as glaucoma and macular degeneration, will continue to increase exponentially. Topical therapy, in the form of daily eye drops, will be replaced with sustained intraocular delivery. Also, we believe second-generation treatment of macular degeneration will employ intraocular injections of compounds that will last months; obviating the need of more frequent, and costly, monthly injections.
IBI’s Verisome® platform has the ability to adapt to current and emerging markets by increasing efficacy of existing medicines, eliminating inefficient topical therapy and avoiding systemic toxicity. The platform offers the unique capability of customized delivery of the therapeutic agent to the target tissue.